Literature DB >> 26944320

A Critical Evaluation of the Methodological Obstacles to Translating Cell-Based Research Into an Effective Treatment for People With Parkinson's Disease.

Stephen Polgar1, Leila Karimi2, Melissa Buultjens1, Meg E Morris1.   

Abstract

The remarkable scientific and technological advances in the field of cell research have not been translated into viable restorative therapies for brain disorders. In this article, we examine the best available evidence for the clinical efficacy of reconstructive intracerebral transplantation in people with Parkinson's disease (PD), with the aim of identifying methodological obstacles to the translation process. The major stumbling block is the fact that the potential contributions of people with neural grafts and the effects of the physical and social environment in which they recover have not been adequately investigated and applied to advancing the clinical stages of the research program. We suggest that the biopsychosocial model along with emerging evidence of targeted rehabilitation can provide a useful framework for conducting research and evaluation that will ensure the best possible outcomes following intracerebral transplantation for PD.
© The Author(s) 2016.

Entities:  

Keywords:  Parkinson’s disease; biopsychosocial approach; intracerebral transplantation; methodology; patient-centered practice; rehabilitation

Mesh:

Year:  2016        PMID: 26944320     DOI: 10.1177/1545968316635277

Source DB:  PubMed          Journal:  Neurorehabil Neural Repair        ISSN: 1545-9683            Impact factor:   3.919


  2 in total

Review 1.  Assessing the Efficacy of Cell Transplantation for Parkinson's Disease: A Patient-Centered Approach.

Authors:  Stephen Polgar; Leila Karimi; Melissa Buultjens; Meg E Morris; Monica Busse
Journal:  J Parkinsons Dis       Date:  2018       Impact factor: 5.568

2.  Evidence-Based Evaluation of the Ethics of Sham Surgery for Parkinson's Disease.

Authors:  Stephen Polgar; Sheeza Mohamed
Journal:  J Parkinsons Dis       Date:  2019       Impact factor: 5.568

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.